Welcome to our dedicated page for KANE BIOTECH ORD news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on KANE BIOTECH ORD stock.
Kane Biotech Inc. (KNBIF) is a biotechnology company dedicated to researching, developing, and commercializing technologies and products that prevent and eliminate microbial biofilms. With a robust portfolio of intellectual property and products like StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™, the company is at the forefront of biofilm research. Recently, Kane Biotech announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel. The company is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) has signed a non-binding offer for the sale of its interest in STEM Animal Health Inc. The terms of the offer remain confidential but specify that Kane will sell its ownership of STEM. The company will receive a deposit of US $625,000 which will be applied towards the sale price of Kane’s interest in STEM. This move allows Kane to focus on human health, specifically wound care and dermatology solutions, two areas where biofilms significantly impact patient health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.36%
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) announced a 29% increase in product and services revenue and a 26% increase in total revenue for the third quarter of 2023. The company's gross profit increased by 17%, but total operating expenses also rose by 35%, leading to a 41% increase in loss compared to the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. (KNE) will announce its Q3 2023 financial results on November 28, 2023. The company focuses on technologies and products to prevent and remove microbial biofilms. Kane Biotech management will host a conference call to review the financial results and discuss business developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) announces the appointment of John Coleman, an accomplished executive with over two decades of senior biotechnology expertise, to its Board of Directors. Dr. Coleman brings scientific and business expertise, having served as the President and CEO of Avivo Biomedical Inc. and co-founded Anandia Labs. His appointment is expected to contribute to Kane's vision of bringing transformative biofilm-targeted products to patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel. The gel combines advanced technology with an affordable price point and is intended for clinical usage in the treatment of chronic wounds. The product will be presented at the Symposium on Advanced Wound Care (SAWC) Fall forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. will unveil the new brand for its coactiv+™ Antimicrobial Wound Gel product at the Symposium on Advanced Wound Care Fall forum. The company will also present a technology poster on the gel's composition. The conference will take place from November 2-5, 2023, in Las Vegas, Nevada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kane Biotech reports 68% increase in product and services revenue and 74% increase in royalties revenue for Q2 2023. Gross profit decreased by 48%. Total revenue decreased by 22% but increased by 61% excluding license revenue. Operating expenses decreased by 36%. Loss for Q2 2023 increased by 22%. The company achieved significant milestones including FDA clearance and distribution agreement for coactiv+™ Antimicrobial Hydrogel, and licensing agreement with Skout’s Honor for Pet Oral Care line. The company also engaged Research Capital Corporation for strategic review and announced a non-brokered private placement offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech to announce Q2 2023 financial results on August 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kane Biotech Inc. has engaged Research Capital Corporation as its exclusive financial advisor to conduct a strategic review process for its STEM Animal Health business division. The company is considering various strategic alternatives to maximize shareholder value, including the sale of assets, a merger, or other business combinations. STEM, formed in partnership with Animalcare Group plc, develops pet oral care products that inhibit tartar formation and kill bacteria. STEM's revenues grew by 31% in 2022 compared to 2021, and royalty revenues grew by 76% during the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of KANE BIOTECH ORD (KNBIF)?
The current stock price of KANE BIOTECH ORD (KNBIF) is $0.08 as of January 21, 2025.
What is the market cap of KANE BIOTECH ORD (KNBIF)?
The market cap of KANE BIOTECH ORD (KNBIF) is approximately 10.6M.
What is Kane Biotech Inc. known for?
Kane Biotech is recognized for its research, development, and commercialization of technologies and products that prevent and remove microbial biofilms.
What are some of the key products offered by Kane Biotech?
Some of the key products offered by Kane Biotech include StrixNB™, DispersinB®, Aledex™, coactiv+™, DermaKB™, and revyve™.
Where is Kane Biotech listed?
Kane Biotech is listed on the TSX Venture Exchange under the symbol 'KNE' and on the OTCQB Venture Market under the symbol 'KNBIF'.
What recent achievements has Kane Biotech announced?
Kane Biotech recently announced the sale of its interest in STEM Animal Health, entered new licensing and distribution agreements, and received US FDA clearance for its revyve™ Antimicrobial Wound Gel.
Who is the President and CEO of Kane Biotech?
The President and CEO of Kane Biotech is Marc Edwards.
What sets Kane Biotech apart in the biotechnology industry?
Kane Biotech stands out for its focus on biofilm research and its innovative portfolio of intellectual property and products.
How can investors participate in Kane Biotech's growth?
Investors can engage with Kane Biotech by trading its shares on the TSX Venture Exchange under the symbol 'KNE' or on the OTCQB Venture Market under the symbol 'KNBIF'.
What recent financial results has Kane Biotech shared?
Kane Biotech announced its fourth quarter and full year 2023 financial results, as well as its first quarter 2024 financial results.
Where can I find more information about Kane Biotech?
For more information about Kane Biotech, visit their website or explore their filings on SEDAR.
What industry does Kane Biotech operate in?
Kane Biotech operates in the biotechnology industry, specifically focusing on technologies and products related to microbial biofilms.
KANE BIOTECH INC ORD